Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. ProQR Therapeutics NV's pretax income for the
three
months ended in Jun. 2026 was $-10.03 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-48.86 Mil.
ProQR Therapeutics NV's pretax margin was -99.36%.
During the past 13 years, ProQR Therapeutics NV's highest Pretax Margin was -147.89%. The lowest was -4546.88%. And the median was -426.94%.
During the past 13 years, ProQR Therapeutics NV's highest Pretax Margin was -147.89%. The lowest was -4546.88%. And the median was -426.94%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProQR Therapeutics NV Pre-Tax Income Related Terms
ProQR Therapeutics NV Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for ProQR Therapeutics NV's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRQR vs NWBO, IMRX, VNDA: Pre-Tax Income Comparison
For the Biotechnology subindustry, ProQR Therapeutics NV's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProQR Therapeutics NV Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where ProQR Therapeutics NV's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProQR Therapeutics NV (PRQR) has a Pre-Tax Income of $-48.86 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on ProQR Therapeutics NV and its competitors.
Is ProQR Therapeutics NV's Pre-Tax Income too high?
ProQR Therapeutics NV's current Pre-Tax Income is $-48.86 Mil. Overall, ProQR Therapeutics NV has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Pre-Tax Income compare to NWBO and IMRX?
ProQR Therapeutics NV's Pre-Tax Income of $-48.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Pre-Tax Income is $-48.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, ProQR Therapeutics NV (PRQR) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.36, compared to a current price of $1.99 — trading 15.7% below its estimated fair value. The current Pre-Tax Income is $-48.86 Mil. ProQR Therapeutics NV's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For ProQR Therapeutics NV (PRQR), the current Pre-Tax Income is $-48.86 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ProQR Therapeutics NV (PRQR) Overvalued in 2026?
Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued.
The current stock price of $1.99 is trading 15.7% below its estimated GF Value™ of $2.36.
GuruFocus considers ProQR Therapeutics NV to be Modestly Undervalued.
Key valuation signals for PRQR:
Pre-Tax Income: $-48.86 Mil
GF Value™: $2.36 vs. price of $1.99 (15.7% below fair value)
No single metric tells the full story. See the PRQR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
50GF Score
Get the complete analysis for PRQR
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRQR has been successfully added to your 
